Delhi Police has dismantled an interstate syndicate selling fake cancer drugs, including high-cost oncology treatments, into government hospital supply chains. Seventeen people have been arrested, and the Rajasthan government has ordered an urgent audit of procurement records at the Rajasthan Medical Services Corporation Limited (RMSCL).
Delhi Police investigators have dismantled a major criminal network involved in the distribution of counterfeit cancer medications across state government hospitals. The operation, which involved the sale of fake life-saving drugs through public healthcare supply chains, has led to the arrest of 17 individuals across several states, including Delhi, Haryana, Maharashtra, Telangana, and Rajasthan. Authorities have seized 588 filled vials and approximately ₹50 lakh in cash, with the total value of the intercepted counterfeit medicines estimated at ₹9 crore.
The racket involved a sophisticated method where the perpetrators intercepted genuine drug vials, emptied their original, life-saving contents, and refilled them with non-medicinal liquids before circulating them back into the supply chain. Laboratory testing has confirmed that the seized samples contained no active pharmaceutical ingredients. The counterfeit labels included several high-cost, advanced oncology treatments such as Avelumab, Darzalex, Imfinzi, Erbitux, Adcetris, and Keytruda, which are commonly prescribed for serious cancer cases.
Following the discovery of compromised batches within the Rajasthan Medical Services Corporation Limited (RMSCL) network, Rajasthan Health Minister Gajendra Singh Khimsar has ordered a comprehensive inquiry. The state government has directed officials to perform a complete audit of drug distribution records, inventory logs, and procurement manifests to identify how these fake products infiltrated the public health procurement system. The investigation aims to determine the extent of the security breach and identify any internal collusion that may have facilitated the entry of these counterfeit products into government facilities.
For the pharmaceutical sector and investors, this incident highlights critical vulnerabilities in the pharmaceutical distribution and procurement ecosystem. While multinational pharmaceutical companies whose brands were used in the scam are victims of intellectual property theft and brand dilution, the event also underscores the growing regulatory focus on supply chain integrity in India. Experts note that such incidents increase pressure on healthcare authorities to adopt more rigorous, technology-driven 'track and trace' mechanisms, such as QR-based serialization and digital inventory verification, to prevent the diversion of genuine stocks and the entry of illicit ones.
The next important monitorable for stakeholders will be the findings of the administrative audit in Rajasthan and any subsequent tightening of procurement policies by state medical corporations. The probe into the supply chain path is ongoing, with investigators working to map the full logistical network of the syndicate to determine if similar breaches have occurred in other states.